Press Releases Daxor Corporation

Equities

DXR

US2394671034

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
9.7 ^USD	+3.19%		+3.19%	+1.04%

Apr. 16	Daxor Corporation Announces Two New Studies Validating the Clinical Benefits of Daxor?s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion	CI
Apr. 10	Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion	Apr. 16	AQ
Daxor Corporation to Exhibit at the Medaxiom Cardiovascular Transforum Conference Spring'24 to Advance Awareness and Further Adoption of Daxor's Blood Volume Diagnostic	Apr. 16	AQ
DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™)	Apr. 15	AQ
Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital	Apr. 10	AQ
Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24	Apr. 01	AQ
Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics	Mar. 25	AQ
Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024	Mar. 22	AQ
Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023	Mar. 18	AQ
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders	Mar. 18	AQ
Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base	Mar. 11	AQ
Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor’s Unique Clinical Utility for Heart Failure Patients	Mar. 08	AQ
Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference	Feb. 26	AQ
Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions	Feb. 12	AQ
Daxor Corporation Closes Q4 2023 with Growth in New Sales to Hospital Systems and Increased Utilization of its BVA-100® Blood Volume Diagnostic Across the U.S. at Existing Accounts	Feb. 07	AQ
Daxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual Meeting	Jan. 29	AQ
Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2024 Critical Care Congress	Jan. 16	AQ
DAXOR AWARDED ADDITIONAL NEW PATENT FOR SMART BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES	Jan. 09	AQ
Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer	Jan. 02	AQ
New Randomized Controlled Trial Demonstrates the Efficacy of Daxor’s BVA Guided-Care in Heart Failure Patients	Nov. 13	AQ
Daxor Corporation Awarded New Patent for Remote Monitoring of Blood Volume	Nov. 09	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Daxor Corporation

Equities

DXR

US2394671034

Press Releases

Filters